Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.55 |
| ▸ | CTSS | P25774 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | PREP | P48147 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21509312 | 0.91 | CTSK (0.51) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL23260554 | 0.90 | CTSK (0.57) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL1505521 | 0.89 | CTSK (0.55) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL247552 | 0.89 | CTSK (0.55) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL8807250 | 0.89 | CTSK (0.55) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL28195152 | 0.88 | CTSK (0.52) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL28083491 | 0.87 | CTSK (0.51) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL13036645 | 0.85 | CTSK (0.50) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL28490772 | 0.85 | CTSK (0.50) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL13708869 | 0.85 | CYP2D6 (0.52) | CTSKCTSSCA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11344858-B2 | Micro-electrolysis reactor for ultra fast, oxidant free, C—C coupling reaction and synthesis of daclatasvir analogs thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2022-05-31 | — | — | US | claimed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| US-11344858-B2 | Micro-electrolysis reactor for ultra fast, oxidant free, C—C coupling reaction and synthesis of daclatasvir analogs thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2022-05-31 | — | — | US | disclosed |
| US-5171837-A | Treatment of autoimmune diseases | KURARAY CO., LTD. (JP) | 1992-12-15 | — | — | US | disclosed |
| US-5132402-A | Immobilized peptide which binds to human antibody to nicotinic acetylcholine receptor | AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1992-07-21 | — | — | US | disclosed |
| EP-0426857-A1 | PEPTIDE AND ADSORBENT COMPRISING SAME IMMOBILIZED ON CARRIER | KURARAY CO., LTD. (JP) | 1991-05-15 | — | — | EP | disclosed |
| US-4889917-A | TREATMENT OF MYASTHENIA GRAVIS | AGENCY OF INDUSTRIAL SCIENCE TECHNOLOGY, MINISTRY OF INTERNATIONAL TRADE & INDUSTRY (JP) | 1989-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344858-B2 | Micro-electrolysis reactor for ultra fast, oxidant free, C—C coupling reaction and synthesis of daclatasvir analogs thereof | CYCS, COASY, CAT | CTSK 733/4885CTSS 106/4885CA2 2602/4885 |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | CTSK 8/4885CTSS 318/4885CA2 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.